20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Key Inclusion Criteria: * 18 to 82 years of age, inclusive * Chronic Kidney Disease with a GFR category of G3a-G5 and not yet on dialysis * eGFR ≥ 10 and ≤ 65 mL/minute/1.73 m2 * Anemia secondary to CKD with an ESA status and a Screening HGB as per protocol * Iron replete with ferritin and TSAT levels as defined per protocol Key Exclusion Criteria: * BMI \> 44.0 kg/m2 * Red blood cell transfusion within 11 weeks prior to the Screening visit * Androgen therapy within the previous 21 days prior to the Screening visit * Intravenous iron within the past 4 weeks prior to the Screening visit * AST or ALT \>1.8x ULN, alkaline phosphatase \>2x ULN, or total bilirubin \>1.5x ULN * Screening ECG with QTc \> 500 msec * Uncontrolled hypertension * Class III or IV congestive heart failure * Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to the Screening visit